Since its discovery nearly 30 years ago\textsuperscript{1-2}, IL-17 has emerged as a key cytokine for host protection against mucosal infections but also as a major pathogenic cytokine and drug target in multiple autoimmune and inflammatory diseases. The IL-17 family comprises six members (IL-17A to IL-17F) that mediate their biological functions through the IL-17 receptors (IL-17RA to IL-17RE). The most studied IL-17 family member is IL-17A (referred to hereafter as IL-17 unless otherwise stated) and it, as well as IL-17F, promotes its biological activities by binding to IL-17RA and IL-17RC (Box 1).

It is now appreciated that IL-17 evolved to mediate innate immunity in invertebrates, which lack adaptive immune systems. However, the inflammatory functions of IL-17 were originally described in mouse models of autoimmune disease, where the initial focus was on IL-17-secreting CD4\textsuperscript{+} T cells — T helper 17 (T\textsubscript{h}17) cells — as a key producer of this cytokine. We now know that CD8\textsuperscript{+} T cells, γδ T cells, innate lymphoid cells (ILCs), natural killer (NK) cells, invariant NK T cells, mucosal associated invariant T cells, mast cells and Paneth cells can also be sources of IL-17. Although T cell receptor (TCR) activation is key for IL-17 production by CD4\textsuperscript{+} and CD8\textsuperscript{+} T cells, IL-17 production by innate immune cells is primarily driven by inflammatory cytokines, especially IL-1β and IL-23 (Box 2). Neutrophils may also be a source of IL-17 during infection\textsuperscript{3}, although this has been questioned by others\textsuperscript{4}.

Studies of experimental autoimmune encephalomyelitis (EAE), a mouse model for multiple sclerosis (MS), suggested that IL-17 was a key pathogenic cytokine in T cell-mediated autoimmune disease pathology\textsuperscript{5-7}. It was subsequently shown that, in EAE, IL-17 is secreted by T\textsubscript{h}17 cells and by γδ T (γδT17) cells\textsuperscript{8,9}. These studies and others detailing pathological roles of IL-17 in human diseases eventually culminated in the development of monoclonal antibodies (mAbs) that target IL-17A, both IL-17A and IL-17F, IL-17RA, or IL-23, a cytokine produced by innate immune cells that promotes the expansion of TH17 cell populations. These mAbs have been licensed for the treatment of certain autoimmune diseases, especially psoriasis, where their efficacy has surpassed traditional non-steroidal anti-inflammatory and tumour necrosis factor (TNF)-blocking drugs\textsuperscript{10-12}.

Clinical trials and real-world use demonstrated an increase in fungal and upper respiratory tract bacterial infections in patients treated with mAbs that block the IL-23–IL-17 pathway\textsuperscript{13-15}. Interestingly, although decreased resistance to infection might have been expected to be more frequent with the use of the anti-IL-12p40 mAb ustekinumab — which blocks both IL-12 and IL-23, thereby inhibiting both T\textsubscript{h}1 and
Box 1 | IL-17 family members

IL-17A was the first member of the IL-17 family to be identified\(^{218}\). The murine Il17 gene, initially called mCTLA8, was cloned from a T cell hybridoma and had 57% homology with the ORF13 gene of the T lymphotropic virus herpesvirus Saimiri\(^{1} \). It was thought that this virus-captured cellular gene was related to the immune system or to cell death and survival. It was then reported that murine and human IL-17A protein was produced by T cells and had cytokine-like properties, including the induction of NF-κB activity and IL-6 production by fibroblasts\(^{218}\). IL-17B to IL-17F were identified based on homology with IL-17A. Furthermore, an additional member, IL-17N, was found in Japanese pufferfish\(^{19}\). The biological function of the IL-17A to IL-17F family is mediated through the IL-17 receptor family, IL-17RA to IL-17RE, with IL-17A and IL-17F binding to IL-17RA and IL-17RC. IL-17A–IL-17F heterodimers can also form a ternary complex with IL-17RA and IL-17RC\(^{218}\). IL-17A has a non-redundant role in the control of many fungal and bacterial infections but is also a key pathogenic cytokine in many autoimmune and inflammatory diseases. IL-17F has overlapping and some distinct functions to IL-17A. For example, blocking IL-17A and IL-17F is more effective than blocking IL-17A alone in treatment of psoriasis but is associated with a higher incidence of oral candidiasis\(^{11}\). IL-17B, which binds to IL-17RB, has anti-inflammatory properties, limiting inflammation in the colon and in allergic asthma; it inhibits IL-25 (IL-17E), another member of the IL-17 cytokine family that also binds to IL-17RB\(^{218}\). IL-25 enhances type 2 cytokine and eosinophil responses in the lung and may be a mediator of allergic airway diseases\(^{212}\). IL-17C, which signals through the IL-17RE–IL-17RA complex, promotes pro-inflammatory cytokine and antibacterial peptide production, especially in response to intestinal pathogens\(^{51}\), and also promotes neutrophilia and inflammatory gene expression in the lungs\(^{222}\).

T\(_{\text{RM}}\) cell-associated responses (FIG. 1) — a comparative analysis revealed that this was not the case\(^{5}\), at least for \textit{Candida} infections, where IL-17 plays a key protective role. A mAb that neutralizes both IL-17A and IL-17F (bimekizumab) that was more effective than an anti-IL-17A mAb (secukinumab) at reducing symptoms in patients with moderate-to-severe psoriasis was associated with a higher incidence of oral candidiasis\(^{11}\). IL-17F has overlapping and some distinct functions to IL-17A. The incidence of oral candidiasis was also higher in patients given bimekizumab as opposed to adalimumab (an anti-TNF mAb) to treat plaque psoriasis\(^{52}\). These studies provided evidence that IL-17A and IL-17F have protective roles against certain infections, especially those caused by fungal pathogens in humans. However, more unequivocal evidence for a host-protective role for IL-17 came from genome-wide association studies (GWAS) that identified single nucleotide polymorphisms (SNPs) in genes coding for IL-17A, IL-17RA, IL-17RC, IL-23 or NF-kB activator 1 (ACT1, an adapter protein downstream of the IL-17R, also known as TRAF3-interacting protein 2 (TRAF3IP2)) that abolished cellular responsiveness to IL-17A and IL-17F. These SNPs were associated with susceptibility to chronic mucocutaneous candidiasis (CMC), a persistent infection of the skin, nails and/or mucosae with \textit{Candida} species\(^{16}\).

Mechanistic studies in animal models of fungal and bacterial infection demonstrated a key protective role for IL-17 at mucosal surfaces, largely mediated by chemokine-driven neutrophil recruitment, antimicrobial peptide (AMP) production and enhanced mucosal barrier function. Thus, IL-17 is not only a pathogenic cytokine in inflammatory diseases but also a key cytokine in host protective immunity to infection. However, even in the setting of infection, IL-17 appears to be a double-edged sword, with defective IL-17 production allowing unchecked expansion of certain pathogens but excessive IL-17 production mediating damaging immunopathology. Several studies have shown that T\(_{\text{RM}}\) cell plasticity may underlie many of the pathological roles of these cells in disease settings. This Review discusses the dual role of IL-17 in driving protective immunity to infection and immunopathology in inflammatory diseases.

T\(_{\text{RM}}\) cell plasticity

T\(_{\text{RM}}\) cells can display plasticity in cytokine production in vivo and can switch from predominantly producing IL-17 to predominantly producing IFN\(_{\gamma}\), thereby resembling T\(_{\text{H}}\)1 cells\(^{11}\). These T\(_{\text{RM}}\) cells are expanded in the joints of patients with rheumatoid arthritis (RA), are functionally distinct from other T\(_{\text{H}}\)1 and T\(_{\text{RM}}\) cell populations, and escape regulation by regulatory T (T\(_{\text{reg}}\)) cells\(^{4} \). T\(_{\text{RM}}\) cell plasticity is influenced by T cell-polarizing cytokines and the inflammatory tissue environment. IL-12 suppresses expression of ROR\(_{\gamma}\)t and IL-17 but enhances IFN\(_{\gamma}\) production by human T\(_{\text{RM}}\) cells\(^{41}\). Fate mapping studies in mice with EAE showed that, as disease developed, T\(_{\text{RM}}\) cells in the spinal cord produced less IL-17 and more IFN\(_{\gamma}\), granulocyte-macrophage colony-stimulating factor (GM-CSF), and TNF\(_{\gamma}\). By contrast, in acute cutaneous \textit{Candida albicans} infection, T\(_{\text{RM}}\) cells stopped producing IL-17 but did not switch to IFN\(_{\gamma}\) production\(^{42}\). Consistent with these findings, we found that CD4+ T cells from Il17a-/- mice could transfer EAE to naive mice\(^{11}\). However, blocking GM-CSF or IFN\(_{\gamma}\) in vivo had little impact on the course of disease whereas blocking IL-17, especially at induction of EAE, prevented development of disease\(^{43}\). Furthermore, in humans, antibodies that target IL-17 are almost as effective as antibodies that target IL-17R or IL-23 in the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis\(^{41,135}\). Therefore, while some T\(_{\text{RM}}\) cells may stop producing IL-17 in vivo, IL-17 still has a pathogenic role in certain autoimmune diseases, either as an effector cytokine or in the priming of T\(_{\text{RM}}\) cells\(^{11}\). Furthermore, studies in an infection model showed that antigen-specific T\(_{\text{RM}}\) cells in the nasal tissue of mice infected with \textit{Bordetella pertussis} predominantly produce IL-17, without IFN\(_{\gamma}\), during the course of infection and persist as tissue resident memory T (T\(_{\text{RM}}\)) cells that still predominantly produce IL-17 upon re-activation many months after bacterial clearance\(^{41}\). This suggests that, at least in certain infection settings, IL-17-secreting CD4+ T cells show a relatively stable phenotype.

There is emerging evidence that cellular metabolism can influence T\(_{\text{RM}}\) cell plasticity. In models of intestinal infection, it was shown that segmented filamentous bacterium (SFB) induced T\(_{\text{RM}}\) cells that produced IL-17A and IL-22 and mainly use oxidative phosphorylation, which is typical of what is seen in quiescent or memory T cells\(^{45}\). These T\(_{\text{RM}}\) cells did not show production of other pro-inflammatory cytokines. By contrast, T\(_{\text{RM}}\) cells induced during infection with \textit{Citrobacter rodentium} were highly glycolytic and exhibited plasticity towards pro-inflammatory cytokine production\(^{46}\). T\(_{\text{RM}}\) cells can also produce IL-10, and such regulatory-type T\(_{\text{RM}}\) cells fail to promote autoimmune inflammation in the EAE model\(^{47}\). This contrasts with the IL-18-stimulated and IL-23-stimulated T\(_{\text{RM}}\) cell
**Box 2 | Cellular sources of IL-17 and their stimuli**

CD4+ T helper 17 (T_{h17}) cells are a key source of IL-17A but can also produce IL-17F, granulocyte-macrophage colony-stimulating factor (GM-CSF), IL-21, IL-22, IFNγ, and tumour necrosis factor (TNF), IL-6 and TGFβ. They were initially described as differentiation factors for T_{h17} cells. However, it was later demonstrated that IL-23 in synergy with IL-1 (IL-1β) or IL-1α or IL-18 in combination with T cell receptor (TCR) ligation promotes activation of mouse and human T_{h17} cells. A population of CD4+ T cells that produce IL-17 without TCR engagement have been called natural T_{h17} (nT_{h17}) cells. These nT_{h17} cells differentiate in the thymus, express the transcription factor RORγt, IL-23R, αβ integrins and CCR6, produce IL-17A, IFNγ and IL-22, and develop in the absence of IL-6 required by inducible T_{h17} cells. nT_{h17} cells mediate host protection at mucosal surfaces through IL-17 and IL-22 production. IL-17-secreting CD8+ T cells produce a similar range of cytokines and are activated in a similar fashion to T_{h17} cells. IL-17-secreting γδ T cells produce the same range of cytokines as T_{h17} cells but are activated by IL-1β and IL-23 without TCR stimulation. A novel population of T cells, that co-expresses αβ and γδ TCRs and high levels of IL-1 and IL-23 receptors, produces IL-17A, GM-CSF and IFNγ following stimulation with IL-1β and IL-23 with or without TCR stimulation. CD1d-dependent invariant NKT cells produce IL-17 in response to glycolipid antigens and IL-1β and TGFβ. Finally, type 3 innate lymphoid cells produce IL-17A and IL-18 in response to IL-1β and IL-23.

**IL-17 in immunity to infection**

**Fungal infections.** There is convincing evidence from IL-17 polymorphism studies in humans and experiments with knockout mice that IL-17-secreting cells play a central role in protective immunity to *Candida* and other fungal pathogens. Individuals with autosomal recessive deficiency in *IL17RA* or mutations in *ACTI* are susceptible to the development of CMC. In addition, CMC is associated with dominant-negative mutations in *STAT3*, which is a key transcription factor in the IL-6, IL-21 and IL-23 signalling pathways required for the development of T_{h17} cells. Furthermore, patients treated with anti-IL-17 mAbs have an increased risk of developing oropharyngeal, oesophageal and cutaneous candidiasis.

Studies in mouse models showed enhanced fungal burden post challenge in mice lacking IL-17 or its receptor. Enhanced kidney infection and poorer survival in *Il17ra−/−* mice after systemic challenge with *C. albicans* was associated with reduced recruitment of neutrophils to the kidneys. Oral candidiasis was more severe in *Il23p19−/−* mice and *Il17ra−/−* mice than in wild-type mice, but was not more severe in *Il12p35−/−* mice, suggesting that T_{h17} cells and not T_{h1}, cells, were required for protection, which was mediated by recruitment of neutrophils and β-defensin production. IL-17RA-deficient humans and mice are highly susceptible to oropharyngeal candidiasis (OPC) and have reduced levels of CXC chemokines and impaired neutrophil recruitment to the oral mucosa. Mice lacking IL-17RA or ACT1 were more susceptible to OPC than *Il17a−/−* mice, suggesting a role for both IL-17F and IL-17A in antifungal immunity in the oropharynx.

Although T_{h17} cells are a key source of IL-17 in fungal infections, in a model of OPC, IL-17-secreting CD8+ T cells compensated for a lack of CD4+ T cells. NK cells and ILCs are also important sources of IL-17A and IL-17F in immunity to fungal infections. However, it has been reported that natural T_{h17} cells and γδ T cells, but not ILCs, are key sources of IL-17 in the control of oral candida infection. In a model of *Aspergillus*-induced keratitis, neutrophils produced and responded to IL-17 to mediate fungal clearance through the production of reactive oxygen species.

IL-17 can also modulate protective T_{h1} cell responses and enhance immunopathology in fungal infections. In a mouse model of infection with *Cryptococcus deneoformans*, a fungal pathogen that can cause fatal meningocerebritis in immunosuppressed patients, early secretion of IL-17 by γδ T cells suppresses the protective T_{h1} cell responses required for fungal clearance and promotes neutrophil-associated inflammation. In a mouse model of skin infection with the fungus *Microsporum canis*, an absence of IL-17 resulted in enhanced T_{h1} cell responses, increased colonization of the epidermis and more severe skin inflammation. Furthermore, patients and mice with AIRE deficiency, which results in enhanced T_{h} cell responses but not enhanced T_{h17} cell responses, show increased susceptibility to mucosal but not systemic fungal infections. Enhanced expression of IFNγ without impaired IL-17 led to defects in mucosal barrier functions that increased susceptibility to infection and inflammation at mucosal sites.

Chronic paracoccidioidomycosis caused by *Paracoccidioides brasiliensis* in humans is associated with neutrophil infiltration into the lungs and the development of granulomatous lesions and pulmonary fibrosis. Depletion of neutrophils in mice reduced the inflammatory responses in lungs and pulmonary fibrosis induced by *P. brasiliensis*. Interestingly the depletion of neutrophils not only reduced levels of pro-inflammatory cytokines, including IL-1α and IL-1β, but also reduced the number of T_{h17} cells in the lungs. This is consistent with a role for IL-1-producing neutrophils and inflammatory monocytes in feedback activation of IL-17 production by T_{h17} cells. These findings demonstrate that IL-17-mediated neutrophil recruitment and activation, while playing a key protective role in many fungal infections, can also contribute to infection-associated immunopathology. In conclusion, IL-17 is clearly a key protective cytokine in anti-fungal immunity but, in certain settings, IFNγ can also have a protective role. However, if not properly regulated, these cytokines can also mediate pathology during fungal infections.
Bacterial infections. Early studies revealed that IL-17 is upregulated in the gastric mucosa of humans infected with *Helicobacter pylori* and in vitro studies showed that it enhanced IL-8 secretion from gastric epithelial cells, which promoted neutrophil chemotaxis. Mechanistic studies by Ye et al. showed that *Ilt17ra−/−* mice but not control animals rapidly succumbed to lethal infection after intranasal challenge with * Klebsiella pneumoniae*. This study was the first to link IL-17 signalling with neutrophil recruitment; *K. pneumoniae*-infected *Ilt17ra−/−* mice had defective neutrophil recruitment associated with reduced production of CXC-chemokine ligand 2 (CXCL2, also known as MIP2) and granulocyte colony-stimulating factor (G-CSF). Furthermore, IL-17 and IL-22 promoted the production of CXC chemokines and G-CSF in the lung and enhanced lung barrier function and resistance to damage. Therefore, IL-17 and IL-22, produced by T<sub>H17</sub> cells, appear to have distinct and overlapping roles in immunity to this bacterial infection, with both cytokines promoting AMP production while IL-22 is more involved in barrier function and IL-17 in neutrophil recruitment. In addition to promoting indirect recruitment of neutrophils by inducing chemokine production, IL-17 can directly activate bacterial killing by neutrophils and macrophages. IL-17-mediated protection against nasopharyngeal colonization with *Streptococcus pneumoniae* involves recruitment and pneumococcal killing by neutrophils. In *B. pertussis* infections in mice, IL-17 plays a critical role in the clearance of primary and secondary infections of the nasal mucosa by recruiting SIGLEC-F<sup>+</sup> neutrophils that have high *NETosis* activity and by inducing AMP production. IL-17 induced by infection with *Francisella tularensis* mediates its protective effects indirectly by promoting IFNγ production, which enhances bacterial killing by macrophages. However, it is possible that this may reflect plasticity of T<sub>H17</sub> cells, with a shift to IFNγ production. There is also evidence that IL-17 synergizes with IFNγ to enhance nitric oxide production by macrophages, thereby promoting protection against *Chlamydia* infection. Furthermore, IL-17 and IFNγ enhance intracellular killing of *B. pertussis* by macrophages and neutrophils. In addition, immunization studies with a candidate *Mycobacterium tuberculosis* vaccine in mice suggested that IL-17-secreting T cells that accumulate in the lung promote chemokine production that recruits T<sub>H17</sub> cells to control the infection. These findings suggest a positive or synergistic influence of IL-17 on the IFNγ response to certain bacterial infections, although it may also reflect T<sub>H17</sub> cell plasticity in vivo.

T<sub>H17</sub> cells may also have more direct antibacterial activities. T<sub>H17</sub> cell clones specific for the skin commensal bacteria *Cutibacterium acnes* secrete extracellular traps that capture bacteria and kill them through secreted antimicrobial proteins. The antimicrobial function of T<sub>H17</sub> cells may also be mediated through their production of IL-26, which kills extracellular bacteria through membrane pore formation. IL-17C, which is largely produced by non-immune cells, such as colon epithelial cells, synergizes with IL-22 to produce AMPs that protect against *C. rodentium*. Furthermore, IL-17C produced by respiratory epithelial cells mediates protective immunity against *Pseudomonas aeruginosa* by inhibiting siderophore activity in the nasal epithelium.

---

**Fig. 1 | Drug targets in the IL-23–IL-17 pathway.** Activation of dendritic cells (DCs) and macrophages through pathogen recognition receptors (PRRs) promotes production of IL-23 and IL-1β, which play a major role in the induction and/or expansion of populations of T helper 17 (T<sub>H17</sub>) cells, IL-17-secreting γδ<sup>T</sup> (γδ<sup>T17</sup>) cells and other IL-17-secreting cells (not shown). By contrast IL-12 production by DCs and macrophages promotes development of T<sub>H17</sub> cells. Monoclonal antibodies (mAbs) that neutralize IL-12p40 (ustekinumab) suppress T<sub>H17</sub> cell as well as T<sub>H17</sub> cell and γδ<sup>T17</sup> cell responses, whereas mAbs that neutralize IL-23 (guselkumab, tildrakizumab and risankizumab) specifically block IL-17-secreting cells. The RORγt transcriptional factor is the master regulator of IL-17 production in diverse cell types and a target for small molecule drugs (SMDs) in development. T<sub>H17</sub> cells, γδ<sup>T17</sup> cells and other IL-17-secreting cells (not shown) co-produce IL-17A and IL-17F and, while most of the focus has been on mAbs specific for IL-17A (secukinumab and ixekizumab), antibodies that neutralize both IL-17A and IL-17F (bimekizumab) are also in clinical use. These, together with mAbs that bind to IL-17RA (brodalumab) and inhibit binding of IL-17A and IL-17F to IL-17RA/IL-17RC, appear to be marginally more effective than anti-IL-17A mAbs. Finally, peptides, macrocycles and other SMDs that target IL-17R or ACT1 are also in development. GM-CSF, granulocyte–macrophage colony-stimulating factor; PAMP, pathogen-associated molecular pattern.
IL-17-secreting CD4+ TRM cells play a key role in sustaining adaptive immunity to bacterial infections, especially in the respiratory tract. These cells confer protection against reinfection of the lung and nose with *B. pertussis*. Current injectable acellular pertussis vaccines fail to induce respiratory TRM cells but this can be reversed by adding an adjuvant that induces IL-1 and IL-23 expression and drives IL-17-secreting TRM cells to the respiratory tissues. Using IL-17A fate mapping mouse models, it has been demonstrated that lung CD4+ TRM cells that confer protective memory against *K. pneumoniae* are derived from Treg cells that can be induced by immunization with heat-killed *K. pneumoniae*. IL-17-secreting TRM cells are more readily induced by previous mucosal infection or with vaccines administered by respiratory rather than by parenteral routes. Respiratory tract-delivered candidate vaccines protect against lung infection with *M. tuberculosis* and against nasal infection with *B. pertussis* largely through induction of IL-17-secreting TRM cells, which mediate their protective effects through the recruitment of neutrophils, activation of AMP production and/or IgA production.

Although CD4+ T cells were identified as a major source of IL-17 in antibacterial immunity, γδ T cells also contribute, especially early in infections at mucosal surfaces. In mouse models, γδ T cells are also a major source of IL-17, which mobilizes neutrophils during peritoneal infection with *Escherichia coli*, liver infection with *Listeria monocytogenes*, intestinal infection with *L. monocytogenes*, cutaneous infection with *S. aureus*, and respiratory infection with *S. pneumoniae* or *B. pertussis*. In a *B. pertussis* infection model, innate Vγ4γ1-γδ T cells provide early IL-17 production, whereas adaptive antigen-specific Vγ4γδ T cells are induced later in infection and become TRM cells that rapidly produce IL-17 and contribute to protection against reinfection. Memory γδT17 cells also mediate protection against reinfection with *S. aureus*. In an *S. aureus* skin infection mouse model, IL-17 produced by Vγδ6γδ T cells induces neutrophil recruitment, the pro-inflammatory cytokines IL-1α, IL-1β and TNF, and host defence peptides.

In addition to its protective role, IL-17 can also promote detrimental inflammatory responses to bacterial infections. In sepsis models, IL-17 was associated with abscess formation following *Bacteroides fragilis* challenge in Treg2-impaired *Stat6* mice; treatment with anti-IL-17 mAbs prevented abscess formation. Similarly, neutralization of IL-17 significantly reduced bacteremia and systemic levels of pro-inflammatory cytokines and chemokines and enhanced survival in mice with sepsis induced by caecal ligation and puncture.

Colonization with the commensal microorganism SFB induces Th17 cells that produce IL-17 and IL-22, which confers resistance against the intestinal pathogen *C. rodentium*. However, Th17 cells induced by SFB can also promote autoimmune arthritis in mice. Th17 cells also have a pathogenic role in infection-induced neutrophilic inflammation associated with allergic airway inflammation in mouse models of neutrophilic asthma in humans. Neutralization of IL-17 prevented enhancement of allergic airway inflammation induced by respiratory infection with *Moraxella catarrhalis*. Finally, IL-36-induced IL-17 production by Th17 cells and γδT17 cells has been implicated in *S. aureus*-induced skin inflammation and atopic dermatitis. Collectively, these findings suggest that, while IL-17 plays a protective role in immunity to many bacteria, excessive IL-17 and associated neutrophilia can result in immunopathology, which can extend to precipitation or exacerbation of inflammatory diseases (FIG. 2).

**Viral infections.** Antigen-specific Th17 cells or IL-17+CD8+ T cells are induced during human infection with various viruses, including influenza virus, HIV-1 and hepatitis C virus (HCV). However, the role of IL-17 in immunity to viruses is still unclear. Evidence of a positive role for IL-17 came from the demonstration that IL-17 enhances resistance to vaccinia virus infection in mice and treatment with anti-IL-17 mAbs exacerbated the viral load. Studies with SIV-infected rhesus macaques revealed that SIV depletes Th17 cells in the ileal mucosa and impairs mucosal immunity to *Salmonella Typhimurium*. Memory α4β7+CD4+ T cells that produce IL-17 are preferentially infected and depleted during acute SIV infection, and the loss of these cells results in a skewing towards a Th1-type response and promotes disease progression. In HIV infection, Th17 cells are reduced and Treg cells enhanced as disease progresses, resulting in impaired immune function. Th17 cells may also be involved in vaccine-induced antiviral immunity, for example, in protection against HSV2 infection by enhancing Th1-type TRM cells in the female genital tract. Th17 cells and IL-17+CD8+ T cells protect against disease and lethality in mice infected with influenza virus by promoting neutrophil influx into the lung. There is also evidence that γδT17 cells may promote clearance of influenza virus from the respiratory tract and protect against infection-associated mortality in neonatal mice by promoting IL-33-induced infiltration of ILC2s and Treg cells, which enhance amphiregulin secretion and tissue repair. In humans, the number of γδT17 cells in bronchoalveolar lavage fluid of patients with influenza virus-associated pneumonia is negatively associated with disease severity.

While the protective role for IL-17 in immunity to viruses is still not clear, there is strong evidence that it can promote inflammatory pathology during viral infection. Virus-specific Th17 cell populations are expanded in the circulation and liver of individuals with HCV infection and, while these cells appear to be regulated by endogenous IL-10 and TGFβ, their numbers correlate with the severity of liver inflammation but not with HCV replication. Hepatic damage is associated with high numbers of Th17 cells and IL-17+CD8+ T cells and a lower frequency of T cells that co-produce IL-17, IL-10, IFNγ and IL-21. Th17 cell populations are also expanded in the circulation and liver of patients with hepatitis B virus infection, and the level of fibrosis in these patients correlates with IL-17 production. IL-17 contributes to liver disease progression by activating stellate cells that promote liver fibrosis. IL-17 can promote hepatocyte necrosis by neutrophil activation in...
Aged mice infected systemically with herpes viruses 87. Similarly, TH17 cells contribute to the pathogenesis of stromal keratitis following cornea infection in mice with HSV1; pathology is alleviated by neutralization of IL-17 (Ref. 88). Furthermore, TH17 cells promote viral replication and myocarditis following coxsackievirus B3 infection in mice; aggressive myocarditis was linked with overactive TH1 cell and CD8+ T cell responses 89. IL-17+CD8+ T cells induced in LCMV- infected mice that had CD8+ T cells deficient in T-bet and Eomes promote inflammation associated with multi-organ neutrophil infiltration and wasting syndrome 90, suggesting that pathogenic IL-17 responses by CD8+ T cells may normally be regulated by IFNγ or Treg cells.

IL-17 can promote lung inflammation associated with influenza virus infection. Patients infected with pandemic H1N1 pdm09 strains of influenza virus had elevated levels of IL-17 and Treg cells, which was associated with acute lung injury, and studies in a mouse model showed that influenza virus- induced lung damage could be ameliorated by neutralization of IL-17 (Ref. 91). Gastroenteritis-like symptoms following lung infection with influenza virus are associated with intestinal microbiota- induced recruitment of TH17 cells that mediate the tissue damage and inflammation that lead to autoimmune diseases. CXCL, CXC-chemokine ligand.

Fig. 2 | Role of IL-17 in protective immunity versus immunopathology. During infection, pathogens release pathogen-associated molecular patterns (PAMPs) that bind to pattern recognition receptors (PRRs) and activate innate immune cells, including macrophages and dendritic cells (DCs), which present foreign peptide antigens to T cells and provide a source of T cell-polarizing cytokines. IL-1β and IL-23 activate T helper 17 (Th17) cells, IL-17-producing CD8+ T cells (IL-17+CD8+), type 3 innate lymphoid cells (ILC3s) and IL-17-secreting γδ T (γδT17) cells, which produce IL-17A and IL-17F as well as other pro-inflammatory cytokines (not shown) that promote the production of neutrophil-recruiting chemokines from epithelial cells (for example, in respiratory tract or intestine). IL-17, together with IFNγ, can also activate macrophages. Activated macrophages and neutrophils phagocytose and kill intracellular bacteria, fungi and protozoan parasites. IL-17A, IL-17F and IL-22 promote the production of antimicrobial peptides (AMPs) and enhance epithelial barrier function. In autoimmune diseases or infection-induced immunopathology, the same responses, triggered by infection or damage during sterile inflammation (damage-associated molecular patterns; DAMPs), can promote auto-antigen-specific Th17 cells and γδT17 cells that produce IL-17A and IL-17F, which in combination with tumour necrosis factor (TNF), act on epithelial cells (for example, keratinocytes in psoriasis) to produce chemokines that recruit neutrophils and macrophages, promoting inflammation. IL-17 also activates the production of pro-inflammatory cytokines and matrix metalloproteinases (MMPs) that mediate the tissue damage and inflammation that lead to autoimmune diseases. CXCL, CXC-chemokine ligand.
In respiratory syncytial virus (RSV) infection, IL-17 has been linked with protective immunity and immunopathology. Humans that resist RSV infection have high pre-symptomatic IL-17 signalling in the nasal mucosa, whereas those that develop disease have neutrophilic inflammation and suppressed Tp17 cell responses. In mice, IL-17 produced by γδ T cells protected against RSV-induced lung inflammation. Furthermore, IL-17 can inhibit airway hyper-responsiveness (AHR) in mice infected with RSV by suppressing type 2 cytokines and eotaxinophils and recruitment to the airways. However, there is evidence that Tp17 cells and neutrophils contribute to lung pathology in RSV-associated AHR through complement activation. IL-17-induced neutrophils have also been implicated in airway inflammation and AHR following infection of mice with enterovirus 68, which may explain the asthma-like symptoms observed in people infected with this virus.

IL-17 may play a pathogenic role in lung inflammation that is caused by severe COVID-19, associated with SARS-CoV-2. Tp17 cell populations are expanded and activated in patients with COVID-19 who develop pulmonary complications. Furthermore, hyperinflammation and lung damage in patients with COVID-19 are associated with enhanced Tp17 cell responses, neutrophilia and increased NETosis. Individuals with SNPs in IL17A that reduce IL-17 expression have decreased susceptibility to ARDS, whereas SNPs in IL17A that result in more IL-17 correlate with enhanced lung inflammation. IL-17 is also elevated in patients with obesity, and this may partly explain the greater risk of developing ARDS associated with COVID-19 that is seen in these patients. IL-17 signalling pathway genes are upregulated in different organs and tissues following SARS-CoV-2 infection. In a mouse model, lung-infiltrating Tp17 cells, macrophages and neutrophils were associated with the increased inflammatory cytokine response that occurred following infection with SARS-CoV-2. A small clinical trial in which patients with COVID-19 were treated with the anti-IL-17 mAb netakimab showed that it reduced lung lesion volume and the need for oxygen support and enhanced survival. However, in another study, treatment with netakimab reduced C-reactive protein levels and improved some clinical parameters but did not reduce the need for mechanical ventilation nor did it enhance survival in patients with COVID-19. Nevertheless, these and other studies suggest that transient inhibition of IL-17 may be a therapeutic option for controlling excessive inflammation during acute viral infections.

Parasitic infections. There is evidence of protective roles for IL-17 in immunity to certain parasites, especially intracellular protozoa, through its roles in promoting the activation of monocytes and/or macrophages. However, IL-17 does not have a major role in mediating immunity to large multicellular parasites and can even promote infection-induced immunopathology in this setting, largely through the recruitment of neutrophils.

IL-17 has a protective role against the protozoan parasite Trypanosoma cruzi in mice, controlling infection-induced inflammation by inhibiting IFNγ production as well as inflammatory responses that mediate hepatic damage by recruiting IL-10-secreting immunosuppressive neutrophils. In humans, high levels of IL-17 are associated with better cardiac function in individuals with Chagas disease, which is caused by infection with T. cruzi. Furthermore, SNPs in the IL17A gene are associated with susceptibility to the development of chronic cardiomyopathy following infection with T. cruzi.

IL-23-induced IL-17, together with IL-22, has protective roles against visceral leishmaniasis in humans, which is caused by the protozoan Leishmania donovani. IL-17 acts synergistically with IFNγ to promote nitric oxide production by macrophages infected with Leishmania infantum, thereby suppressing the parasitic infection in mice. However, IL-17 produced by γδ T cells can inhibit host control of intracellular infection of monocytes with L. donovani. It has also been demonstrated that TGFβ and IL-35 production from Treg cells controls chronic visceral leishmaniasis by downregulating Tp17 cells. Furthermore, IL-17 can promote disease progression in mice infected with Leishmania major through recruitment of neutrophils. Similarly, immunopathology associated with mucosal leishmaniasis, a severe form of cutaneous leishmaniasis, is mediated by IL-17 production and neutrophil recruitment and associated with low concentrations of IL-10. Furthermore, IL-17-producing ILCs activated by skin microbiota promote skin inflammation in cutaneous leishmaniasis.

Although IL-17 can promote protection against the protozoan parasite Toxoplasma gondii by recruiting neutrophils, antibody-mediated neutralization of IL-17 in disease-susceptible C57BL/6 mice reduced inflammation and enhanced survival during T. gondii infection, and this was associated with augmented production of IFNγ and IL-10. Furthermore, intraocular inflammation and uveitis during toxoplasmosis is suppressed by neutralizing IL-17; this was associated with enhanced induction of T-bet and IFNγ and a reduced parasite load. Thus, the balance between IL-17 and IFNγ can determine the outcome of T. gondii infection. Collectively, these studies suggest that IL-17 has a protective role against intracellular parasites but that, in certain settings, IL-17 can also mediate immunopathology.

Protective immunity against large multicellular parasites, especially helminths, is mediated by type 2 immune responses and, although IL-17-producing T cells are induced during helminth infection, they predominantly mediate pathology. However, IL-17 has been shown to have protective as well as pathogenic roles during infection of the lung with the nematode Nippostrongylus brasiliensis. IL-17 signalling via ACT1 in epithelial cells promotes the expansion of ILCs and drives type 2 immunity against N. brasiliensis. Furthermore, early IL-17 production by ILCs promotes the development of protective type 2 responses by suppressing IFNγ but, later in infection, IL-17 also limits excessive type 2 responses, especially the activation of ILC2. IL-1β-induced IL-17 production by γδ T cells, induced by chitinase-like proteins, also has a protective role against infection.
with *N. brasiliensis*123. However, IL-17 can mediate helminth-induced lung inflammation by recruiting neutrophils124. IL-17 is also a major mediator of the immunopathology seen in mice16 and humans125 following infection with schistosomes, which are parasitic flatworms. *Schistosoma mansoni* egg antigen–induced immunopathology is associated with IL-17–mediated neutrophil recruitment and is restrained by IFNγ126. Antibody neutralization of IL-17 in mice infected with *Schistosoma japonicum* reduced worm and egg burdens as well as the percentages of neutrophils and eosinophils in liver granulomas while increasing the proportions of macrophages and lymphocytes127. Therefore, the role of IL-17 in parasitic infection tends to be more damaging than protective, especially against large extracellular parasites.

**IL-17 in autoimmunity and inflammation**

The sections above have considered the beneficial and detrimental effects of IL-17 induction in response to different types of infection. Below, I discuss the involvement of IL-17 in driving the pathology seen in autoimmune and other inflammatory diseases.

**Inflammatory skin and joint diseases.** IL-17 has a well-established role in the pathology of psoriasis, psoriatic arthritis and ankylosing spondylitis. SNPs in *IL17RA* or in its promoter that enhance IL-17 responses have been identified as a risk factor for psoriasis13,11 and ankylosing spondylitis18. Studies in a mouse model of psoriasis, induced by topical application of the Toll-like receptor 7 (TLR7)/TLR8 ligand imiquimod, showed that disease was attenuated in mice deficient for IL-23 or IL-17R130. T<sub>Îµ17</sub> cells are found in the dermis of psoriasis skin lesions130 and mediate skin inflammation in mice and humans following recognition of self–lipid antigens presented by CD1a130. Furthermore, IL-17–producing CD8<sup>+</sup> T cells with a tissue-resident phenotype are found in the synovial fluid of patients with psoriatic arthritis133. Other cellular sources of IL-17 — including γδ T cells, neutrophils and mast cells — and IL-23-driven induction of IL-22, may also be involved in the pathology of these diseases134.

A range of highly effective therapeutics that target the IL-23–IL-17 pathway are in widespread clinical use. Clinical trials revealed that antibodies that target IL-12p40 (ustekinumab), IL-17A (secukinumab and ixekizumab), IL-17A and IL-17F (bimekizumab), IL-17RA (brodalumab), and IL-23 (guselkumab, tilikracizumab and risankizumab) are effective for the treatment of moderate-to-severe psoriasis (TABLE 1). Blocking IL-17A and IL-17F with bimekizumab resulted in greater skin clearance in patients with psoriasis than blocking IL-17A alone with secukinumab14. Therapeutics that target the IL-23–IL-17 pathway are also efficacious for psoriatic arthritis and ankylosing spondylitis2.

Hidradenitis suppurativa, a chronic inflammatory skin disease of hair follicles, is characterized by substantial skin infiltration of T<sub>Îµ17</sub> cells that express CD161, a lineage marker for T<sub>Îµ17</sub> cells145. Open-label pilot clinical trials with secukinumab showed moderate efficacy in patients with hidradenitis suppurativa135, and phase III trials are ongoing. Although secukinumab was not effective in treating alopecia areata147, there is off-label use of IL-17-blocking drugs for the treatment other skin disorders, including Behcet disease, lichen planus, pustular psoriasis, impetigo herpetiformis and pityriasis rubra pilaris.

RA is probably the disease where there was most promise but least return on IL-17 as a therapeutic target. High concentrations of IL-17 are present in the synovial fluid of patients with RA, where it promotes osteoclastogenesis138. Furthermore, T<sub>Îµ17</sub> cells from patients with RA promote the release of IL-6, IL-8 and matrix metalloproteinases (MMPs) by synovial fibroblasts139. In mouse models of RA, T<sub>Îµ17</sub> cells and γδT17 cells were found to mediate autoimmune arthritis140,141, and blocking IL-17 attenuated joint inflammation and cartilage destruction142. However, clinical trials in patients with RA using antibodies that target IL-17 or IL-23/IL-12p40 had low or no efficacy, respectively143,144. The limited therapeutic benefit of IL-17–targeted drugs in RA is not clear but may reflect disease heterogeneity or the fact that ex-T<sub>Îµ17</sub> cells (which produce IFNγ but not IL-17) rather than classical T<sub>Îµ17</sub> cells are enhanced in the synovial fluid of patients with RA148.

**MS and EAE.** Many of the initial discoveries on T<sub>Îµ17</sub> cells and on the pathogenic role of IL-17 in autoimmune disease were made in the EAE mouse model of MS. Although there was some scepticism around the precise role of IL-17 in EAE and MS and difficulty in translating findings from mice to humans, recent studies have provided convincing evidence that IL-17 is a key pathogenic cytokine in EAE and a major drug target in MS. IL17 mRNA is expressed in immune cells in the cerebrospinal fluid of patients with MS149. Furthermore, T<sub>Îµ17</sub> cells cross the blood–brain barrier in individuals with MS and accumulate in areas of active lesions150. A proof-of-concept study in patients with relapsing-remitting MS showed that treatment with the anti-IL-17 mAb secukinumab reduced the number of cumulative new lesions by 67%151. Surprisingly, this has not been followed up in larger clinical trials despite the encouraging results from patients with MS and convincing data from the EAE model.

In the EAE model, T<sub>Îµ17</sub> cells, driven by IL-23 and IL-1Î² or IL-18, are a key T cell population that mediates pathology152,157. However, there is also evidence that autoantigen–specific T<sub>Îµ17</sub> cells can mediate EAE149 or enable T<sub>Îµ17</sub> cells to enter the central nervous system (CNS)155, which may involve IFNγ-mediated enhancement of VLA4 (the α4β1 integrin) expression on T<sub>Îµ17</sub> cells156. γδT17 cells are also found in high numbers in the CNS of mice with EAE, especially early in disease, and their depletion prevented the development of disease1. Furthermore, T cells co-expressing γδ and γδ TCRs are recruited to the CNS early in EAE, and these highly activated T cells act as an initial trigger for inflammatory responses by providing a very early source of IL-17 (REF. [157]). Collectively, these findings suggest that EAE pathology is not driven exclusively by IL-17 and T<sub>Îµ17</sub> cells and that other cytokines and cells, including CD8<sup>+</sup> T cells and γδ T cells, may be involved.
Table 1 | IL-17 pathway-targeted therapies in autoimmunity and inflammation

| Indication                  | Evidence of role for IL-17 pathway in animal models                                                                 | Blocking IL-17 pathway in animal models                                                                 | Evidence of role for IL-17 pathway in humans                                                                 | mAb to IL-17 pathway in clinical trials/human use                                                                 | Refs./Clinical trials |
|-----------------------------|-----------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------|-----------------------|
| Psoriasis                   | Disease ameliorated in IL17a, IL17ra, IL23 KO mice                                                                 | Anti-IL-17 mAbs and inhibitors of RORγt decrease disease in psoriasis model                             | IL17RA SNP associations; T<sub>R</sub>7 cells and γδ<sub>T</sub>17 cells present in skin lesions               | Ustekinumab, secukinumab, ixekizumab, bimekizumab, brodalumab, guselkumab, tildrakizumab and risankizumab: approved | 10-12,170,130-132,134 |
| Psoriatic arthritis         | Evidence from psoriasis models (above)                                                                                 | Evidence from psoriasis models (above)                                                                   | T<sub>R</sub>7 cells, IL-17-CD8<sup>+</sup>T cells, γδ<sub>T</sub>17 cells and ILC3 in skin lesions and synovial fluid | Ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and risankizumab: approved | 13,135               |
| Ankylosing spondylitis      | IL-23 induces enthesitis, γδ<sub>T</sub>17 cells involved                                                            | Anti-IL-17 mAbs decrease joint inflammation                                                                | IL23R, STAT3 and CARD9 SNP association                                                                          | Secukinumab, ixekizumab and brodalumab: approved                                                                           | 22,127,137           |
| Rheumatoid arthritis        | T<sub>R</sub>7 cells and γδ<sub>T</sub>17 cells promote joint inflammation                                              | Anti-IL-17 mAbs decrease joint inflammation                                                                | IL-17 in synovial fluid                                                                                       | Ustekinumab or guselkumab: no efficacy; secukinumab: low efficacy                                                          | 136-144              |
| Multiple sclerosis          | T<sub>R</sub>7 cells and γδ<sub>T</sub>17 cells transfer disease; EAE decreased in IL17a KO mice                         | Anti-IL-17 mAbs at induction decrease EAE                                                                 | T<sub>R</sub>7 cells and γδ<sub>T</sub>17 cells in brain lesions                                               | Secukinumab: some efficacy, phase II                                                                                         | 5-8,12,146,147,155, NCT01433250 |
| Inflammatory bowel disease  | T<sub>R</sub>7 cells and ILC3 increase in qut; IL23 and Act1 KO mice show reduced colitis                              | Anti-IL-12p40 or anti-IL-23p19 mAbs decrease colitis, anti-IL-17 mAbs increase colitis                    | IL23R SNPs association; T<sub>R</sub>7 cells increase in Crohn’s disease and ulcerative colitis                | Ustekinumab: approved; secukinumab and brodalumab increase disease                                                          | 14,15-16,18,185      |
| TID                         | T<sub>R</sub>7 cells increase disease in NOD mice                                                                     | Anti-IL-17 mAbs decrease disease                                                                         | T<sub>R</sub>7 cells expanded in blood in patients with TID                                                    | Ustekinumab and kizukumab: phase II/III recruiting                                                                           | 171                  |
| Uveitis                     | T<sub>R</sub>7 cells involved in pathology; decrease disease in IL17a KO mice                                           | Anti-IL-17 mAbs increase disease                                                                           | Elevated IL-17 and IL-23 in blood                                                                              | Secukinumab: phase III trials did not meet primary end point                                                                | 166-170, NCT00685399 |
| Atopic dermatitis           | T<sub>R</sub>7 cells and IL-17 levels increase in acute skin lesions                                                  | NA                                                                                                       | IL-17 increase in skin lesions, increased T<sub>R</sub>7 cells in blood                                         | Secukinumab: phase II completed                                                                                              | 198                  |
| Neutrophilic asthma         | IL-17 promotes neutrophil influx in mouse allergic asthma model                                                     | Anti-IL-17 mAbs decrease neutrophil influx                                                                | IL17A SNP association; T<sub>R</sub>7 cells increase in blood                                                  | Secukinumab and brodalumab: phase II trials terminated                                                                       | 196-197, NCT01478360, NCT01902290 |
| GVHD                        | Transfer of T<sub>R</sub>7 cells induces GVHD                                                                      | Anti-IL-23 mAbs or RORγt inhibitors decrease GVHD                                                        | Increased T<sub>R</sub>7 cells in blood of patients with GVHD                                                   | Ustekinumab: phase II completed, some benefit                                                                               | 202                  |
| Hidradenitis suppurativa    | NA                                                                                                                   | NA                                                                                                       | Substantial skin infiltrating CD161⁺ T<sub>R</sub>7 cells                                                   | Secukinumab: moderate efficacy, open-label trial; bimekizumab and secukinumab: phase III, ongoing | ECT200000417942, ECT201800206326, NCT03713632 |
| AD                          | γδ<sub>T</sub>17 cells accumulate in brain in animal model; T<sub>R</sub>7 cells increase AD-like pathology           | Anti-IL-17 mAbs decrease short-term memory deficit and neuro-inflammation                                | Increased T<sub>R</sub>7 cells in blood in mild cognitive impairment                                           | Ustekinumab in AD: status unknown                                                                                           | 205-209, NCT02835716 |
| FLD                         | Obesity-associated IL-17 increases FLD                                                                             | Anti-IL-17 mAbs decrease liver damage                                                                      | IL-17 increased in obesity/liver disease                                                                     | Secukinumab: completed                                                                                                      | 206                  |
| COVID-19                    | T<sub>R</sub>7 cells associated with inflammatory cytokine response                                                 | NA                                                                                                       | T<sub>R</sub>7 cells increased in lungs in severe COVID-19/obesity                                              | Netakimab: attenuated disease                                                                                               | 105-107              |

γδ<sub>T</sub>17, IL-17-secreting γδ T; AD, Alzheimer disease; EAE, experimental autoimmune encephalomyelitis; FLD, fatty liver disease; GVHD, graft-versus-host disease; ILC3, type 3 innate lymphoid cell; KO, knockout; mAbs, monoclonal antibodies; NA, not applicable; NOD, non-obese diabetic mouse; SNP, single nucleotide polymorphism; T<sub>R</sub>7, T helper 17 cell; TID, type 1 diabetes.
It has also been suggested that IL-17 does not play a major role in EAE. Overexpression of IL-17 in CD4+ and CD8+ T cells did not enhance the severity of EAE, and anti-IL-17 mAb treatment of Il17f−/− mice did not affect the development of EAE. However, treatment with anti-IL-17 mAb attenuated disease when administered at induction of disease or before relapse in the relapsing-remitting model of EAE but had little effect when administered at the peak of disease. Similarly, treatment with anti-IL-17 mAb significantly reduced clinical scores when administered at induction but not after onset of clinical signs in the MOG-induced chronic EAE model. Furthermore, III17a−/− mice are resistant to induction of EAE. A recent study from my group provided one explanation for some of the previous anomalies. We found that IL-17 has a priming role in EAE by inducing chemokines that recruit IL-18-producing neutrophils and inflammatory monocytes that promote IL-17 production by γδ T cells, which kick-start the inflammatory cascade that mediates EAE. It has also been suggested that the cells that mediate CNS pathology in EAE are GM-CSF+ IFNγ+ CXCR6+ pathogenic T17 cells derived from stem-like TCF1+ IL-17+ SLAMF6+ T cells that have trafficked from the intestine, where they were maintained by the microbiota. This is consistent with our demonstration that, while IL-17 is required to initiate inflammation, it is redundant at the effector stage of disease. This does not rule out IL-17 being an important drug target in MS; on the contrary, blocking the IL-17 pathway may suppress induction or re-activation of T17 cells and γδT17 cells and may therefore be an effective approach, as suggested by a clinical trial, for the prevention of relapse in patients with relapsing-remitting MS.

**Inflammatory bowel disease.** The expression of IL-17 is significantly increased in the serum and inflamed mucosa of patients with active ulcerative colitis or Crohn’s disease. Furthermore, GWAS studies showed that a non-synonymous SNP in the IL23R gene is associated with Crohn’s disease. Studies in mouse models of colitis suggested that IL-17 produced by T17 cells and/or ILCs and stimulated by IL-18 and IL-23 plays a critical role in chronic intestinal inflammation. Furthermore, deletion of ACT1 in gut epithelial cells reduced IL-17-induced expression of CXCL1 (also known as KC), IL-6, and CXCL2 and attenuated colitis in mice. However, there is also evidence that IL-23 promoted IFNγ, which synergizes with IL-17 to mediate intestinal inflammation. Alternatively, pathology may be mediated by ex-T17 cells, which are T17 cells that have switched to become IFNγ-producing cells.

These and other studies led to the testing of IL-17 and IL-23 targeted therapies for the treatment of inflammatory bowel disease (IBD), and ustekinumab has been approved for treatment of Crohn’s disease. However, clinical trials with secukinumab or brodalumab in patients with IBD resulted in enhanced Candida infections and increased intestinal inflammation. Although IL-17 and T17 cells can drive inflammation that damages the gut mucosa, IL-17 and IL-22 also play protective roles in limiting fungal and bacterial infection of the gut. Studies in mouse models showed that blocking IL-17 exacerbated intestinal inflammation, whereas blocking IL-12p40 or IL-23p19 conferred protection. The protective effect of IL-17 was lost in mice lacking functional ACT1 in gut epithelial cells, which is consistent with a role for IL-17 and IL-22 in protecting barrier integrity of the intestinal epithelium. However, it has also been demonstrated that IL-17F may have a pathogenic role in murine colitis and that blocking IL-17F but not IL-17A induced protective Treg cells through modification of the microbiota.

**Other autoimmune and inflammatory diseases.** Studies in the experimental autoimmune uveitis mouse model showed that IL-17 plays a key role in pathology, although disease could be induced by both T17 and T17 cells. Clinical trials with secukinumab in patients with non-infectious uveitis did not meet the primary efficacy end point. T17 cells also have a pathogenic role in autoimmune diabetes. Treatment with anti-IL-17 mAbs or recombinant IL-25 (which inhibits T17 cells) attenuated disease. Furthermore, T17 cells are expanded in the blood of patients with type 1 diabetes and IL-17 enhances inflammatory responses in human islet cells. Clinical trials with anti-IL-12p40 and anti-IL-17 mAbs are ongoing in patients with type 1 diabetes. Evidence is emerging of a role for IL-17 in other autoimmune diseases, such as systemic lupus erythematosus, and in a broad range of diseases where inflammation is at the core of the pathology, including neurological diseases, metabolic diseases, asthma and cancer (Box 3 and Table 2).
Reviews

| Indication                  | Evidence of role for IL-17 pathway in animal models | Blocking IL-17 pathway in animal models or in vitro | Evidence of role for IL-17 pathway in humans | Refs. |
|-----------------------------|----------------------------------------------------|---------------------------------------------------|-------------------------------------------|-------|
| ASD                         | TLR-induced IL-17 in pregnant mice increase ASD in offspring | Anti-IL-17 mAbs in pregnancy decrease ASD in offspring | T_{reg} Cell ratio in blood correlates with disease severity | 207,208 |
| PD                          | T_{17} cells exacerbate dopaminergic neurodegeneration | Anti-IL-17 mAbs decrease IL-17-mediated cell death of PD-derived neurons | IL17A SNP association, increased T_{17} in PD blood | 209–211 |
| Atherosclerosis             | IL-17 and γδT17 cells promote high-fat diet-induced atherosclerosis | Anti-IL-17 mAbs decrease atherosclerotic lesions | IL-17 increased disease in patients with hyperlipidaemia | 212,215 |
| IS                          | IL-17”γδ T cells infiltrate lesion site after IS and mediate ischaemic brain tissue damage | Anti-IL-17 mAbs decrease BBB damage induced by γδ T cells that secrete IL-17 | IL17RC SNP association, IL-17 increased in serum during IS | 214–216 |
| Sepsis                      | T_{17} and γδT17 cells decrease bacteria load but increase pathology | Anti-IL-17 mAbs decrease sepsis | IL-17 increased in human sepsis | 217,218 |
| Influenza virus associated inflammation | IL-17 increases lung inflammation and gastroenteritis during infection | Anti-IL-17 mAbs decrease influenza virus-induced lung damage | Not known | 90–95 |
| Stromal keratitis           | T_{17} cells increase HSV1-induced stromal keratitis | Anti-IL-17 mAbs decrease stromal keratitis | Not known | 98 |
| Parasitic infections        | IL-17A increases helminth-induced neutrophil recruitment and lung damage | Anti-IL-17 mAbs decrease neutrophils and liver granulomas | IL-17 increases schistosomiasis-associated immunopathology | 214–217 |

| Indication                  | Evidence of role for IL-17 pathway in animal models | Blocking IL-17 pathway in animal models or in vitro | Evidence of role for IL-17 pathway in humans | Refs. |
|-----------------------------|----------------------------------------------------|---------------------------------------------------|-------------------------------------------|-------|
| ASD                         | TLR-induced IL-17 in pregnant mice increase ASD in offspring | Anti-IL-17 mAbs in pregnancy decrease ASD in offspring | T_{reg} Cell ratio in blood correlates with disease severity | 207,208 |
| PD                          | T_{17} cells exacerbate dopaminergic neurodegeneration | Anti-IL-17 mAbs decrease IL-17-mediated cell death of PD-derived neurons | IL17A SNP association, increased T_{17} in PD blood | 209–211 |
| Atherosclerosis             | IL-17 and γδT17 cells promote high-fat diet-induced atherosclerosis | Anti-IL-17 mAbs decrease atherosclerotic lesions | IL-17 increased disease in patients with hyperlipidaemia | 212,215 |
| IS                          | IL-17”γδ T cells infiltrate lesion site after IS and mediate ischaemic brain tissue damage | Anti-IL-17 mAbs decrease BBB damage induced by γδ T cells that secrete IL-17 | IL17RC SNP association, IL-17 increased in serum during IS | 214–216 |
| Sepsis                      | T_{17} and γδT17 cells decrease bacteria load but increase pathology | Anti-IL-17 mAbs decrease sepsis | IL-17 increased in human sepsis | 217,218 |
| Influenza virus associated inflammation | IL-17 increases lung inflammation and gastroenteritis during infection | Anti-IL-17 mAbs decrease influenza virus-induced lung damage | Not known | 90–95 |
| Stromal keratitis           | T_{17} cells increase HSV1-induced stromal keratitis | Anti-IL-17 mAbs decrease stromal keratitis | Not known | 98 |
| Parasitic infections        | IL-17A increases helminth-induced neutrophil recruitment and lung damage | Anti-IL-17 mAbs decrease neutrophils and liver granulomas | IL-17 increases schistosomiasis-associated immunopathology | 214–217 |

| Indication                  | Evidence of role for IL-17 pathway in animal models | Blocking IL-17 pathway in animal models or in vitro | Evidence of role for IL-17 pathway in humans | Refs. |
|-----------------------------|----------------------------------------------------|---------------------------------------------------|-------------------------------------------|-------|
| ASD                         | TLR-induced IL-17 in pregnant mice increase ASD in offspring | Anti-IL-17 mAbs in pregnancy decrease ASD in offspring | T_{reg} Cell ratio in blood correlates with disease severity | 207,208 |
| PD                          | T_{17} cells exacerbate dopaminergic neurodegeneration | Anti-IL-17 mAbs decrease IL-17-mediated cell death of PD-derived neurons | IL17A SNP association, increased T_{17} in PD blood | 209–211 |
| Atherosclerosis             | IL-17 and γδT17 cells promote high-fat diet-induced atherosclerosis | Anti-IL-17 mAbs decrease atherosclerotic lesions | IL-17 increased disease in patients with hyperlipidaemia | 212,215 |
| IS                          | IL-17”γδ T cells infiltrate lesion site after IS and mediate ischaemic brain tissue damage | Anti-IL-17 mAbs decrease BBB damage induced by γδ T cells that secrete IL-17 | IL17RC SNP association, IL-17 increased in serum during IS | 214–216 |
| Sepsis                      | T_{17} and γδT17 cells decrease bacteria load but increase pathology | Anti-IL-17 mAbs decrease sepsis | IL-17 increased in human sepsis | 217,218 |
| Influenza virus associated inflammation | IL-17 increases lung inflammation and gastroenteritis during infection | Anti-IL-17 mAbs decrease influenza virus-induced lung damage | Not known | 90–95 |
| Stromal keratitis           | T_{17} cells increase HSV1-induced stromal keratitis | Anti-IL-17 mAbs decrease stromal keratitis | Not known | 98 |
| Parasitic infections        | IL-17A increases helminth-induced neutrophil recruitment and lung damage | Anti-IL-17 mAbs decrease neutrophils and liver granulomas | IL-17 increases schistosomiasis-associated immunopathology | 214–217 |

γδT17, IL-17-secreting γδ T; ASD, autism spectrum disorder; BBB, blood–brain barrier; IS, ischaemic stroke; mAbs, monoclonal antibodies; PD, Parkinson disease; SNP, single nucleotide polymorphism; T_{17} cell, T helper 17 cell; TLR, Toll-like receptor; T_{reg}, regulatory T.

**Regulation of IL-17 activity**

Even though IL-17 is produced in response to most if not all infections and that this cytokine is central to the pathogenesis of many autoimmune diseases, most people do not succumb to these diseases. This reflects the existence of efficient host tolerance and regulatory mechanisms to control autoreactive T_{17} cells and IL-17-induced inflammatory responses. Such mechanisms include T_{reg} cells, alternatively activated macrophages, anti-inflammatory cytokines and immune-checkpoints that regulate T cell responses [Fig. 3]. Thymically derived FOXP3+ T_{reg} cells and peripherally induced T_{reg} cells play key roles in regulating IL-17 to prevent autoimmunity and infection-induced immunopathology. T_{reg} cells are co-induced with effector T cells and the outcome of these diseases can depend on their balance.

Children infected with *H. pylori* have significantly lower IL-17 production, neutrophil infiltration and gastric inflammation but higher levels of IL-10 production and FOXP3+ T_{reg} cells than in *H. pylori*-infected adults, suggesting that T_{reg} cells control inflammatory T_{17} cell responses in vivo. In patients with MS, there is a normal overall frequency of FOXP3+ T_{reg} cells in the circulation and these cells do not suppress T_{17} cells; however, there is a reduced frequency of and loss of suppressive function in a subset of CD39-expressing FOXP3+ T_{reg} cells that have been shown to inhibit pathogenic FOXP3+ T_{reg} cells [174].

There is also evidence that CD39+CD25+CD4+ T cells with low levels of PD1 expression suppress IL-17 production in patients with brain inflammation linked to human T lymphotropic virus type 1 (HTLV1)-associated myelopathy/tropical spastic paraparesis [175]. T_{reg} cells may also be controlled by migration to the small intestine, where they are either eliminated or converted to regulatory-type T_{17} cells [176]. These cells are potent producers of IL-10 and capable of suppressing potentially pathogenic effector T cells. T_{reg} cells that co-express RORyt and FOXP3 also play a suppressive role in intestinal inflammation in mice [177]. However, the relative contribution of conventional T_{reg} cells, RORyt+FOXP3+ T_{reg} cells or regulatory-type T_{17} cells in controlling inflammation in humans is still unclear.

There is an established role for anti-inflammatory cytokines in regulating IL-17. IL-10 limits protective T_{17} cell responses during influenza virus infection; IL10−/− mice have enhanced T_{17} cell responses and show better survival following infection with influenza virus without excessive inflammation [178]. IL-10 plays a key role in limiting IL-17-mediated pathology in Lyme arthritis following *Borrelia burgdorferi* infection [179].
IL-10 and IFNγ also regulate IL-17 production in the setting of autoimmunity. Regulatory-type T<sub>n</sub>17 cells that co-express IL-17 and IL-10 are generated under the influence of IL-6 and TGFβ in mice with EAE and these cells are non-pathogenic, whereas T<sub>n</sub>17 cells that develop in EAE under the influence of IL-1β and IL-23 do not secrete IL-10 and induce potent disease.<sup>227</sup> Co-production of IL-17 with IL-10 may allow T<sub>n</sub>17 cells to control infection without driving damaging pathology, whereas the inflammatory pathology in autoimmunity may only occur when IL-17 is produced in the absence of IL-10. This also in part explains how the same cell type can be involved in autoimmune and protective immunity to infection.

Although identified as a T<sub>n</sub>1 cell-promoting cytokine, IL-27 can regulate T<sub>n</sub>17 cells. IL-27 suppresses the development of T<sub>n</sub>17 cells during RSV infection.<sup>179</sup> In T. gondii infection, IL-27 limits IL-17-mediated chronic immunopathology in the CNS.<sup>180</sup> The protective effect of IFNβ to induce IL-27 expression<sup>181</sup> has been linked with IL-35 production by regulatory B cells.<sup>182</sup>

The development of T<sub>n</sub>17 cells can be regulated by environmental factors. For example, high-salt conditions promote the development of highly pathogenic T<sub>n</sub>17 cells that secrete GM-CSF, TNF and IL-2 through activation of nuclear factor of activated T cells 5 (NFAT5) and serum/glucocorticoid-regulated kinase 1 (SGK1).<sup>183</sup> Furthermore, T<sub>n</sub>17 cell responses can be negatively regulated downstream of the receptors for IL-17 or IL-23. A20, an inhibitor of signalling downstream of TNF receptors and TLRs, attenuates IL-17-mediated NF-κB and MAPK pathways by deubiquitinating the E3 ubiquitin ligase TRAF6, downstream of the IL-17R.<sup>191</sup>

Evidence is emerging of a role for immune-checkpoint inhibitors in regulating IL-17 production. Treatment of malignancies with anti-PD1/anti-PDL1 or anti-CTLA4 antibodies is associated with the development of autoimmune and inflammatory manifestations<sup>184</sup> that can be mediated by IL-17 [REF.185]. In mouse models, anti-PD1 mAbs enhanced graft-versus-host disease mediated by T<sub>n</sub>17 cells and T<sub>n</sub>1 cells<sup>186</sup>, whereas intratracheal treatment of lung tumour-bearing mice with anti-PD1 antibodies activated T<sub>n</sub>17 cells and γδT<sub>17</sub> cells.<sup>187</sup> However, the precise role of immune-checkpoint inhibitors in regulating T<sub>n</sub>17 cells and γδT<sub>17</sub> cells in autoimmunity and infection and the mechanisms involved remain to be defined.

As well as genetic factors, exposures to pathogens and commensal microorganisms have a significant impact on the balance between protective versus pathogenic and regulatory immune responses and the development of autoimmune diseases. Recent interpretations of the hygiene hypothesis have suggested that infection with anti-inflammatory commensal bacteria or helminth parasites can attenuate autoimmune diseases mediated by T<sub>n</sub>17 cells. Infection with the intestinal helminth *Heligmosomoides polygyrus* suppresses IL-17 production that mediates colitis through IL-4 and IL-10 induction.<sup>188</sup> Infection of mice with the helminth *Fasciola hepatica* suppresses T<sub>n</sub>17 cells and γδT<sub>17</sub> cells that mediate EAE through helminth induction of TGFβ<sup>187</sup>, type 2 cytokines and eosinophils.<sup>189</sup> In humans, helminth infections can reduce disease severity in patients with MS and this has been linked with IL-35 production by regulatory B cells.<sup>190</sup>

The development of T<sub>n</sub>17 cells can be regulated by environmental factors. For example, high-salt conditions promote the development of highly pathogenic T<sub>n</sub>17 cells that secrete GM-CSF, TNF and IL-2 through activation of nuclear factor of activated T cells 5 (NFAT5) and serum/glucocorticoid-regulated kinase 1 (SGK1).<sup>183</sup> Furthermore, T<sub>n</sub>17 cell responses can be negatively regulated downstream of the receptors for IL-17 or IL-23. A20, an inhibitor of signalling downstream of TNF receptors and TLRs, attenuates IL-17-mediated NF-κB and MAPK pathways by deubiquitinating the E3 ubiquitin ligase TRAF6, downstream of the IL-17R.<sup>191</sup>
Moreover, development of T_{H}17 cells can be suppressed by SOCS3, which negatively regulates IL-23-mediated STAT3 phosphorylation.

Much of the focus on the regulation of IL-17 production has been on T_{H}17 cells. However, innate immune cells, including γδT_{H}17 cells and hybrid αβ-γδ T cells, are an important early source of IL-17 in EAE and S. aureus infection. These cells are activated by IL-1β and IL-23, independent of TCR engagement, and may therefore escape the mechanisms that regulate conventional CD4+ and CD8αβ T cells, which often involve suppression of antigen-presenting cell function. Further work will be required to unravel the regulation of IL-17 production by unconventional T cells and their possible role in precipitating autoimmunity.

**Conclusions and future perspectives**

T cells and innate immune cells that produce IL-17 play key protective roles in immunity to fungal, bacterial, and many viral and parasitic pathogens but can also mediate damaging infection-associated immunopathology or, through the influence of genetic and environmental factors, lead to the development of autoimmune or other chronic inflammatory diseases. IL-17 produced during infection with pathogens or commensal microorganisms, although not specific for self-antigens, may indirectly precipitate or exacerbate autoimmune diseases by priming autoreactive T_{H}17 cells. In fact, IL-17 induced by infection or during sterile inflammation may promote inflammatory responses that are central to many different pathologies, including cardiovascular and neuroinflammatory diseases, neutrophilic asthma, cytokine storms and sepsis, and IL-17 is therefore a drug target in these diseases (Table 2).

All of the currently licensed therapeutics in the IL-17–IL-17R pathway are mAbs. Some have been associated with side effects, including enhanced intestinal inflammation in patients with IBD treated with secukinumab or brodalumab, suicidal thoughts in some patients with psoriasis treated with brodalumab, and enhanced Candida or upper respiratory tract infections in patients treated with a range of mAbs that target the IL-17–IL-17R pathway. Oral bioavailable small molecule drugs (SMDs) have advantages not only regarding cost of production and ease of delivery but also regarding the potential of reduced infection-related side effects. Unlike biologics, which chronically block IL-17 production, SMDs are more likely to transiently blunt IL-17 production, which may break the cycle of inflammation without suppressing the protective effects of IL-17 against infection. However, off-target toxicity can be an issue with some SMDs.

SMDs against RORγt suppress IL-17 production by human and mouse T_{H}17 cells, IL-17–CD8α T cells, and γδT_{H}17 cells and attenuate imiquimod-induced psoriasis in mice. However, safety issues seem to have halted their clinical progression. SMDs or peptide inhibitors of the IL-17A–IL-17R interaction can block IL-17A signalling in primary human keratinocytes. However, these have not progressed to animal model or clinical studies. Therefore, there is a need for safe and effective oral bioavailable SMDs that block the IL-17–IL-17R pathway.

Because of the dual role of IL-17 in protective immunity and damaging inflammation, an alternative, more targeted approach may be to exploit the host’s natural immunoregulatory mechanisms that selectively suppress IL-17 responses to self-antigens or in specific diseased tissues. Selective induction of T_{reg} cells or cell-based therapies with in vitro-expanded T_{reg} cells have already shown proof-of-principle in animal models and, although yet to deliver major success in human clinical trials, they may provide a safe and effective approach for the treatment of autoimmune diseases in humans.

Published online 5 July 2022

---

1. Rouvier, E., Luciani, M. F., Mattei, M. G., Denizot, F. & Golstein, P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus Saimiri gene. J. Immunol. 150, 5445–5456 (1993).
2. Yao, Z. et al. Herpesvirus Saimiri encodes a new cytokine. J. Immunol. 150, 811–821 (1995).
3. Taylor, P. R. et al. Activation of neutrophils by autocrine IL-17A:IC7 receptor interactions during fungal infection is regulated by IL-6, IL-23, RORγt and dectin-2. Nat. Immunol. 15, 143–151 (2014).
4. Tamassia, N. et al. A reappraisal on the potential ability of human neutrophils to express and produce IL-17 family members in vitro: failure to reproducibly detect it. Front. Immunol. 9, 795 (2018).
5. Langrish, C. L. et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 235–240 (2005).
6. This was the first report to describe a population of IL-17-secreting CD4+ T cells (later called T_{H}17 cells) that are distinct from T_{T}1 cells, driven by IL-23, and mediate pathology in an autoimmune disease.
7. Sutton, C., Breton, C., Keogh, B., Mills, K. H. & Lavelle, E. C. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J. Exp. Med. 203, 1685–1691 (2006).
8. Lalor, S. J. et al. Caspase-1-processed cytokines IL-1β and IL-18 promote IL-17 production by gammadelta T cells that mediate autoimmunity. J. Immunol. 186, 5738–5748 (2011).
9. Sutton, C. E. et al. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity 31, 531–541 (2009).
10. This study demonstrates that IL-17-producing γδ T cells activated by the cytokines IL-1 and IL-23 without TCR activation play a key role in pathology of experimental autoimmune encephalomyelitis.
11. Ribot, J. C. et al. CD72 is a thymic determinant of the autocrine IL-17A-IL-17RC interactions during infection with pathogens or commensal microorganisms, although not specific for self-antigens, may indirectly precipitate or exacerbate autoimmune diseases by priming autoreactive T_{H}17 cells. In fact, IL-17 induced by infection or during sterile inflammation may promote inflammatory responses that are central to many different pathologies, including cardiovascular and neuroinflammatory diseases, neutrophilic asthma, cytokine storms and sepsis, and IL-17 is therefore a drug target in these diseases (Table 2).
12. All of the currently licensed therapeutics in the IL-17–IL-17R pathway are mAbs. Some have been associated with side effects, including enhanced intestinal inflammation in patients with IBD treated with secukinumab orbrodalumab, suicidal thoughts in some patients with psoriasis treated with brodalumab, and enhanced Candida or upper respiratory tract infections in patients treated with a range of mAbs that target the IL-17–IL-17R pathway.
13. Oral bioavailable small molecule drugs (SMDs) have advantages not only regarding cost of production and ease of delivery but also regarding the potential of reduced infection-related side effects. Unlike biologics, which chronically block IL-17 production, SMDs are more likely to transiently blunt IL-17 production, which may break the cycle of inflammation without suppressing the protective effects of IL-17 against infection. However, off-target toxicity can be an issue with some SMDs.
14. SMDs against RORγt suppress IL-17 production by human and mouse T_{H}17 cells, IL-17–CD8α T cells, and γδT_{H}17 cells and attenuate imiquimod-induced psoriasis in mice. However, safety issues seem to have halted their clinical progression. SMDs or peptide inhibitors of the IL-17A–IL-17R interaction can block IL-17A signalling in primary human keratinocytes. However, these have not progressed to animal model or clinical studies. Therefore, there is a need for safe and effective oral bioavailable SMDs that block the IL-17–IL-17R pathway.
15. Because of the dual role of IL-17 in protective immunity and damaging inflammation, an alternative, more targeted approach may be to exploit the host’s natural immunoregulatory mechanisms that selectively suppress IL-17 responses to self-antigens or in specific diseased tissues. Selective induction of T_{reg} cells or cell-based therapies with in vitro-expanded T_{reg} cells have already shown proof-of-principle in animal models and, although yet to deliver major success in human clinical trials, they may provide a safe and effective approach for the treatment of autoimmune diseases in humans.
21. McGinley, A. M. et al. Interleukin-17A serves a priming role in autoimmunity by recruiting IL-17-producing myeloid cells that promote pathogenic T cells. *Immunity* 52, 342–356.e6 (2020).

22. "This study demonstrates that IL-17 promotes recruitment of IL-17-secreting myeloid cells that prime pathogenic γδT and Th17 cells in autoimmune disease."

23. Bär, E., Whitney, P. G., Moor, K., Reis e Sousa, C. & LeibundGut-Landmann, S. Cutting edge: IL-17 regulates systemic arthritis by promoting induction of Th17 cells. *J. Immunol.* 192, 514–520 (2014).

24. Marchitto, M. C. et al. Clonal Vγ6Vδ4+ T cells promote IL-17-mediated immunity against Staphylococcus aureus skin infection. *Proc. Natl. Acad. Sci. USA* 116, 10917–10926 (2019).

25. Aujla, S. J. et al. IL-22 mediates mucosal host defense against Gram-negative bacterial pneumonia. *Nat. Med.* 16, 275–281 (2010).

26. Wu, H. J. et al. Gut-resident segmented filamentous bacteria drive autoreactive T helper 17 cells. *Immunity* 52, 815–827 (2020).

27. Fehr, M. A. et al. Adverse functions of IL-17A in experimental sepsis. *Faseb J.* 22, 1928–2025 (2008).

28. Rowan, A. G. et al. Segmented filamentous bacteria trigger IL-17-mediated inflammatory bowel disease. *Nat. Rev. Gastroenterol. Hepatol.* 11, 531–544 (2014).

29. Kader, M. et al. Alpha4γδT17 cell immunity and host resistance to the intracellular pathogen Mycobacterium tuberculosis. *J. Exp. Med.* 206, 919–933 (2009).

30. Roy, T. et al. Rare loss-of-function variants in HLA-G, a cell surface antigen, are associated with lower risk for systemic lupus erythematosus. *Nat. Genet.* 46, 488–494 (2014).

31. Murphy, M. A. et al. Staphylococcus aureus infection of mice expands a population of memory γδ T cells that are protective against subsequent infection. *J. Immunol.* 192, 2682–2688 (2014).

32. McGinley, A. M. et al. Segmented filamentous bacteria (SFB) drive IL-17-dependent skin inflammation. *Science Transl. Med.* 12, eaaw2672 (2020).

33. Nematow, A. et al. Gut- and skin-resident memory γδ T cells orchestrate the innate immune response to secondary oral Listeria monocytogenes infection. *Proc. Natl. Acad. Sci. USA* 113, 8502–8507 (2016).

34. Zhang, Y. et al. IL-17A synergizes with IFN-γ to drive IL-17A expression and attenuated host defense against fungal infection. *Mucosal Immunol.* 10, 1056–1066 (2017).

35. Lin, Y. et al. Interleukin-17 is required for T helper 1 cell-mediated immunity against systemic infection and autoimmunity, and suggests that IL-17 may have a priming role in autoimmunity by recruiting IL-17-producing myeloid cells that prime pathogenic γδT and Th17 cells in autoimmune disease."

36. "This study demonstrates that IL-17 promotes recruitment of IL-17-secreting myeloid cells that prime pathogenic γδT and Th17 cells in autoimmune disease."

37. "The intestine harbors functionally distinct homestatic tissue-resident and inflammatory Th17 cells. *Immunity* 51, 77–89.e6 (2019).

38. "Esplugues, E. et al. Control of Th17 cells occurs in the small intestine. Nature 475, 514–518 (2011)."

39. "McGeachy, M. J. et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(17)-cell-mediated pathology. *Nat. Immunol.* 8, 1390–1397 (2007)."

40. "Lee, Y. et al. Induction and molecular signature of pathogenic T cells in Th17 cells *Nat. Immunol.* 13, 991–999 (2012)."

41. "Sato, K. et al. Production of IL-17A at innate immune sites is essential for the protective immune response against fungal infection. *Mucosal Immunol.* 11, 1483–1492 (2021).

42. "Omenetti, S. et al. The intestine harbors functionally distinct homestatic tissue-resident and inflammatory Th17 cells. *Immunity* 51, 77–89.e6 (2019)."

43. "Esplugues, E. et al. Control of Th17 cells occurs in the small intestine. Nature 475, 514–518 (2011)."

44. "McGeachy, M. J. et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(17)-cell-mediated pathology. *Nat. Immunol.* 8, 1390–1397 (2007)."

45. "Lee, Y. et al. Induction and molecular signature of pathogenic T cells in Th17 cells *Nat. Immunol.* 13, 991–999 (2012)."

46. "Sato, K. et al. Production of IL-17A at innate immune sites is essential for the protective immune response against fungal infection. *Mucosal Immunol.* 11, 1483–1492 (2021)."

47. "Omenetti, S. et al. The intestine harbors functionally distinct homestatic tissue-resident and inflammatory Th17 cells. *Immunity* 51, 77–89.e6 (2019)."

48. "Esplugues, E. et al. Control of Th17 cells occurs in the small intestine. Nature 475, 514–518 (2011)."

49. "McGeachy, M. J. et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(17)-cell-mediated pathology. *Nat. Immunol.* 8, 1390–1397 (2007)."

50. "Lee, Y. et al. Induction and molecular signature of pathogenic T cells in Th17 cells *Nat. Immunol.* 13, 991–999 (2012)."

51. "Sato, K. et al. Production of IL-17A at innate immune sites is essential for the protective immune response against fungal infection. *Mucosal Immunol.* 11, 1483–1492 (2021)."

52. "Omenetti, S. et al. The intestine harbors functionally distinct homestatic tissue-resident and inflammatory Th17 cells. *Immunity* 51, 77–89.e6 (2019)."

53. "Esplugues, E. et al. Control of Th17 cells occurs in the small intestine. Nature 475, 514–518 (2011)."

54. "McGeachy, M. J. et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(17)-cell-mediated pathology. *Nat. Immunol.* 8, 1390–1397 (2007)."

55. "Lee, Y. et al. Induction and molecular signature of pathogenic T cells in Th17 cells *Nat. Immunol.* 13, 991–999 (2012)."

56. "Sato, K. et al. Production of IL-17A at innate immune sites is essential for the protective immune response against fungal infection. *Mucosal Immunol.* 11, 1483–1492 (2021)."

57. "Omenetti, S. et al. The intestine harbors functionally distinct homestatic tissue-resident and inflammatory Th17 cells. *Immunity* 51, 77–89.e6 (2019)."

58. "Esplugues, E. et al. Control of Th17 cells occurs in the small intestine. Nature 475, 514–518 (2011)."

59. "McGeachy, M. J. et al. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(17)-cell-mediated pathology. *Nat. Immunol.* 8, 1390–1397 (2007)."

60. "Lee, Y. et al. Induction and molecular signature of pathogenic T cells in Th17 cells *Nat. Immunol.* 13, 991–999 (2012)."

61. "Sato, K. et al. Production of IL-17A at innate immune sites is essential for the protective immune response against fungal infection. *Mucosal Immunol.* 11, 1483–1492 (2021)."

62. "Omenetti, S. et al. The intestine harbors functionally distinct homestatic tissue-resident and inflammatory Th17 cells. *Immunity* 51, 77–89.e6 (2019)."
Habibi, M. S. et al. Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infection. Science 370, eaab9301 (2020).

Huang, H., Saravanan, J., Yu, D., Shaw, A. J. & Cormier, S. The gamma delta T cell-derived IL-17A and inflammasome activation during early respiratory syncytial virus infection in infants. J. Immunol. 196, 650–656 (2015).

Newcomb, D. C. et al. IL-17A inhibits airway reactivity induced by respiratory syncytial virus infection during allergic asthma. J. Allergy. 88, 717–725 (2013).

Bera, M. M. et al. Th17 cytokines are critical for respiratory syncytial virus-associated airway hyperresponsiveness through regulation by complement C3a and tachykinin. J. Immunol. 187, 4245–4255 (2016).

Rajauf, C. et al. Enterovirus D68 infection induces IL-17-dependent neutrophilic airway inflammation and hyperresponsiveness. JCI Insight 3, e126882 (2018).

Wu, X. et al. IL-17F regulates IL-17A expression in COVID-19 patients with pulmonary sequelea. miR 12b, e1059921 (2021).

Sadeghi, A. et al. Th17 and Treg cells function in SARS-CoV-2 patients compared with healthy controls. J. Cell. Physiol. 256, 2829–2839 (2021).

Masso-Silva, J. A. et al. Maspin, a breast cancer metastasis suppressor, modulates neutrophil extracellular trap formation in critically ill coronavirus disease 2019 (COVID-19) patients: a case series and early control of IL-17A in the neutrophilic inflammatory milieu for spontaneous development of IL-17 T cells that cause autoimmune arthropitits. J. Exp. Med. 204, 41–47 (2020).

Li, W. et al. Treatment with a neutralizing anti-IL-17A antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 69, 2381–2391 (2017).

Blanco, F. J. et al. Secukinumab in active rheumatoid arthritis: a phase III randomized, double-blind, active comparator-and placebo-controlled study. Arthritis Rheum. 69, 1144–1155 (2017).

Smolen, J. S. et al. A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Ann. Rheum. Dis. 76, 831–839 (2017).

Hou, J. et al. Increased expression of interleukin 17A in rheumatoid arthritis patients. J. Clin. Immunol. 37, 1159–1166 (2016).

Koonse, M. A., Carlson, T. J., Andjelkovic, A. V. & Segal, B. M. IL-17A and IL-25-modulated T cells induce distinct types of EAE based on histology, CNS chemokine profile, and response to cytokine inhibition. J. Immunol. 205, 1535–1549 (2015).

O’Connor, R. A. et al. Cutting edge. Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 181, 3750–3754 (2008).

Dungan, L. S., McGuinness, N. C., Boon, L., Lynch, A. M. & Milis, K. H. Intra-IFNγ treatment with maintained experimental autoimmune encephalomyelitis: a role for NK cells and M1 macrophages. J. Immunol. 184, 2903–2917 (2010).

Edwards, S. C. et al. A population of proinflammatory T cells coexpresses γδ TCR and γ+ T cells receptors in mice and humans. J. Exp. Med. 207, e20150834 (2020).

Haak, S. et al. IL-17A and IL-25 do not contribute vitaly to autoimmune neuro-inflammation in mice. J. Clin. Invest. 119, 61–69 (2019).

Marrugat-Suau, S. et al. Anti-IL-17A treatment reduces clinical score and VCAM-1 expression detected by in vivo magnetic resonance imaging in chronic relapsing EAE. Neurom. 182, 2071–2081 (2015).

Yang, X. O. et al. Regulation of inflammatory responses by IL-17F. J. Exp. Med. 205, 1063–1075 (2008).

Schindel, A. et al. Stem-like intestinal Th17 cells give rise to pathogenic effector T cells during chronic intestinal inflammation. Nat. Med. 20, 635–642 (2014).

Fujino, S. et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52, 65–70 (2003).

Duerer, R. H. et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Cell 164, 616–626 (2016).

Yen, D. et al. IL-25 is essential for T cell-mediated colitis and promotes inflammation via IL-17A and IL-6. J. Clin. Invest. 116, 1510–1516 (2006).
158. Coccia, M. et al. IL-17 mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+ Th17 cells. J. Exp. Med. 209, 1595–1609 (2012).

159. Zhang, H. J. et al. Interleukin-23-independent IL-17 effector function in a spontaneous murine colitis model. Inflamm. Bowel Dis. 21, 973–986 (2015).

160. Lee, J. S. et al. Interleukin-23-independent IL-17 production regulates intestinal epithelial permeability. J. Exp. Med. 213, 2723–2738 (2016).

161. Tangu, C. et al. Suppression of IL-17F, but not IL-17A, mediates an anti-inflammatory and anti-neurodegeneration in a model of Parkinson’s disease. J. Immunol. 184, 2261–2270 (2010).

162. Sommer, A. et al. Th17 lymphocytes induce neuronal cell death in a PLSG6 mouse model of Parkinson’s disease. Cell Stem Cell 25, 123–131.e6 (2019).

163. Gu-Palido, J. et al. Interleukin-25 receptor expressing γδ T cells locally promote early atherosclerotic lesion formation and plaque necrosis in mice. Cardiovasc. Res. https://doi.org/10.1093/cvr/cvab359 (2021).

164. Wang, Y. et al. Interleukin-17-producing CD4+ T cells promote inflammatory response and foster disease progression in hyperplastic nares and atherosclerotic mice. Front. Cardiovasc. Med. 8, 667168 (2021).

165. Dory, S. et al. γδ T cells aggravate blood-brain barrier injury via IL17A in experimental ischemic stroke. Neurosci. Lett. 776, 136563 (2022).

166. Tian, X. et al. Interleukin-25-mediated C gene polymorphism reduces treatment effect and promotes poor prognosis of ischemic stroke. Biosci. Rep. 39, BSSE035 (2019).

167. Lu, L. et al. Vγ4 T cell-derived IL-17A is essential for amplification of inflammatory cascades in ischemic brain tissue after stroke. Inflammation. 96, 107678 (2021).

168. Geepert, A. Lehmann, S., Wirth, E. & Rondeau, J. M. The human IL-17 A/F heterodimer: a two-faced cytokine in antiinflammatory immunity and airway inflammation in childhood asthma. Mucosal Immunol. 9, 64–457 (2016).

169. McKinstry, K. K. et al. IL-10 deficiency unleashes an illness-specific Th17 response and enhances survival against high-dose challenge. J. Immunol. 182, 7353–7369 (2004).

170. Hansen, E. S. et al. Interleukin-10 (IL-10) inhibits Borrelia burgdorferi-induced IL-17 production and attenuates IL-17-mediated Lyme arthritis. Infect. Immun. 81, 6012–6020 (2013).

171. de Almeida Nagata, D. E. et al. IL-27-mediated regulation of IL-17 controls the development of respiratory syncytial virus–associated pathogenesis. Am. J. Pathol. 184, 1807–1818 (2014).

172. Stumhofer, J. S. et al. Interleukin 27 negates the development of interleukin 17-producing Th cells during experimental inflammatory exacerbation of the central nervous system. Nat. Immunol. 7, 957–965 (2006).

173. Swennen, C. M. et al. IL-27 mediates the response to IFN-γ therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav. Immun. 25, 149–157 (2011).

174. Carlino, M. S., Larkin, J. & Long, G. V. Immune checkpoint inhibitors in melanoma. Lancet Oncol. 19, 1002–1014 (2021).

175. Wang, Y. N. et al. Elevated levels of IL-17A and IL-17F in plasma and bronchoalveolar lavage fluid are associated with checkpoint inhibitor pneumonitis in patients with non-small cell lung cancer. Oncol. Lett. 19, 611–621 (2020).

176. Fujiwara, H. et al. Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental autoimmune encephalomyelitis. J. Immunol. 193, 2565–2573 (2014).

177. Li, Q. G., Ng. P. T. & Eglemeir, N. K. Anti-17A antibody-mediated abrogation of IL-17CC prevents cryopyrin-associated periodic syndrome. PLoS ONE 12, e0165024 (2017).

178. Zhang, H. J. et al. Interleukin-10 (IL-10) inhibits Th17/Th1-mediated experimental autoimmune encephalomyelitis. J. Immunol. 165, 1757–1768 (2000).

179. Luger, D. et al. Either a Th17 or a Th1 effector function mediates Th17/Treg cells imbalance and their related cytokines in Han Chinese population. J. Immunol. 193, 1111–1115 (2019).

180. Nie, K. et al. Polymorphisms in immune/inflammatory cytokine genes are related to Parkinson’s disease with cognitive impairment in the Han Chinese population. Neurosci. Lett. 541, 111–115 (2015).

181. Reynolds, A. D. et al. Regulatory T cells attenuate Th17 cell-mediated neuroinflammation and neurodegeneration in a model of Parkinson’s disease. J. Immunol. 184, 2261–2270 (2010).

182. Sommer, A. et al. Th17 lymphocytes induce neuronal cell death in a PLSG6 mouse model of Parkinson’s disease. Cell Stem Cell 25, 123–131.e6 (2019).

183. Gu-Palido, J. et al. Interleukin-25 receptor expressing γδ T cells locally promote early atherosclerotic lesion formation and plaque necrosis in mice. Cardiovasc. Res. https://doi.org/10.1093/cvr/cvab359 (2021).

184. Wang, Y. et al. Interleukin-17-producing CD4+ T cells promote inflammatory response and foster disease progression in hyperplastic nares and atherosclerotic mice. Front. Cardiovasc. Med. 8, 667168 (2021).

185. Dory, S. et al. γδ T cells aggravate blood-brain barrier injury via IL17A in experimental ischemic stroke. Neurosci. Lett. 776, 136563 (2022).

186. Tian, X. et al. Interleukin-25-mediated C gene polymorphism reduces treatment effect and promotes poor prognosis of ischemic stroke. Biosci. Rep. 39, BSSE035 (2019).

187. Lu, L. et al. Vγ4 T cell-derived IL-17A is essential for amplification of inflammatory cascades in ischemic brain tissue after stroke. Inflammation. 96, 107678 (2021).

188. Geepert, A. Lehmann, S., Wirth, E. & Rondeau, J. M. The human IL-17 A/F heterodimer: a two-faced cytokine in antiinflammatory immunity and airway inflammation in childhood asthma. Mucosal Immunol. 9, 64–457 (2016).

189. McKinstry, K. K. et al. IL-10 deficiency unleashes an illness-specific Th17 response and enhances survival against high-dose challenge. J. Immunol. 182, 7353–7369 (2004).

190. Hansen, E. S. et al. Interleukin-10 (IL-10) inhibits Borrelia burgdorferi-induced IL-17 production and attenuates IL-17-mediated Lyme arthritis. Infect. Immun. 81, 6012–6020 (2013).

191. de Almeida Nagata, D. E. et al. IL-27-mediated regulation of IL-17 controls the development of respiratory syncytial virus–associated pathogenesis. Am. J. Pathol. 184, 1807–1818 (2014).

192. Stumhofer, J. S. et al. Interleukin 27 negates the development of interleukin 17-producing Th cells during experimental inflammatory exacerbation of the central nervous system. Nat. Immunol. 7, 957–965 (2006).

193. Swennen, C. M. et al. IL-27 mediates the response to IFN-γ therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav. Immun. 25, 149–157 (2011).

194. Carlino, M. S., Larkin, J. & Long, G. V. Immune checkpoint inhibitors in melanoma. Lancet Oncol. 19, 1002–1014 (2021).
Tanaka, S. et al. Natural occurring IL-17 producing T cells regulate the initial phase of neutrophil mediated airway responses. J. Immunol. 183, 7523–7530 (2009).

Miyazaki, Y. et al. IL-17 is necessary for host protection against acute-phase Trypanosoma cruzi infection. J. Immunol. 185, 1150–1157 (2010).

Martin, B., Hirota, K., Cua, D. J., Stockinger, B. & Veldhoen, M. Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals. Immunity 31, 521–530 (2009).

Michel, M. L. et al. Identification of an IL-17 producing NK1.1(neg) iNKT cell population involved in airway neutrophilia. J. Exp. Med. 204, 995–1001 (2007).

Monteiro, M., Almeida, C. F., Agua-Doce, A. & Graca, L. Induced IL-17-producing invariant NKT cells require activation in presence of TGF-β and IL-1β. J. Immunol. 190, 805–811 (2013).

Kim, H. Y. et al. Interleukin-17 producing innate lymphoid cells and the NLRP3 inflammasome facilitate obesity-associated airway hyperreactivity. Nat. Med. 20, 54–61 (2014).

Chen, L. et al. IL-23 activates innate lymphoid cells to promote neonatal intestinal pathology. Mucosal Immunol. 8, 390–402 (2015).

Vitiello, G. A. & Miller, G. Targeting the interleukin-17 immune axis for cancer immunotherapy. J. Exp. Med. 217, e20190456 (2020).

Zhao, J., Chen, X., Herjan, T. & Li, X. The role of interleukin-17 in tumor development and progression. J. Exp. Med. 217, e20190297 (2020).

Hymowitz, S. G. et al. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J. 20, 5532–5541 (2001).

Jin, M. et al. Interleukin-17 and Th17 lymphocytes directly impair motoneuron survival of wildtype and FUS-ALS mutant human iPSCs. Int. J. Mol. Sci. 22, 8042 (2021).

Luo, H. et al. Interleukin-17 regulates neuron-glial communications, synaptic transmission, and neuropathic pain after chemotherapy. Cell Rep. 29, 2384–2397.e5 (2019).

Xu, L. et al. Interleukin-17A contributed to the damage of blood-CNS barriers during Streptococcus suis Meningitis. Mol. Neurobiol. 59, 2116–2128 (2022).

Robert, M. & Mossec, P. Effects of interleukin 17 on the cardiovascular system. Autoimmun. Rev. 16, 984–991 (2017).

Kohlgruber, A. C. et al. γδ T cells producing interleukin-17A regulate adipose regulatory T cell homeostasis and thermogenesis. Nat. Immunol. 19, 464–474 (2018).

Schmidt, T., Luebbe, J., Paust, H. J. & Panzer, U. Mechanisms and functions of IL-17 signaling in renal autoimmune diseases. Mol. Immunol. 104, 90–99 (2018).

Acknowledgements
K.H.G.M. acknowledges funding from Science Foundation Ireland (16/IA/4468 and 20/SPP/3685). He is grateful to L. Borkner, D. Jazayeri, C. Ní Chasaide, W. McCormack and J. Fletcher for comments and discussion.

Competing interests
K.H.G.M. is a co-founder and shareholder in a Biotech start-up company involved in the development of anti-inflammatory therapeutics.

Peer review information
Nature Reviews Immunology thanks J. Ribot and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© Springer Nature Limited 2022